** ASX-listed shares of Aroa Biosurgery rise as much as 15.4% to A$0.6, their highest since Aug. 12

** NZ's Medical products maker expects to be operating cash flow positive in the second half of FY25

** Co says FY25 normalised EBITDA guidance maintained at NZ$2 mln ($1.21 mln) to NZ$6 mln

** Says, FY25 revenue guidance maintained between NZ$80 mln and NZ$87 mln

** ARX to release financial results for H1 FY25 on Nov. 26

** Stock down 30.7% YTD

($1 = 1.6543 New Zealand dollars)

(Reporting by Ayushman Ojha in Bengaluru)

((Ayushman.ojha@thomsonreuters.com;))